Excessive bleeding associated with trauma, surgery or bleeding disorders is the most common preventable cause of death in modern society. The primary treatment for excessive bleeding today is transfusion, which replaces lost blood but does not halt the bleeding. Transfusion is expensive and blood supplies are often limited; the cost of transfusions and associated complications total approximately $27 billion in the United States each year. Alternative therapies to halt bleeding are limited, costly and associated with thrombotic complications, or they are restricted in their use to local applications.
RxMP’s Red Cell Microparticles
RxMP holds exclusive rights to technology for the manufacture and use of novel hemostatic agents based on red cell-derived microparticles (RMPs). Such RMPs are found normally at low concentrations in the bloodstream, and clinical findings have shown that individuals at high risk of excessive bleeding who have high natural levels of RMPs are less likely than others to experience spontaneous bleeds
The company’s RMPs are manufactured inexpensively from packed red blood cells through a readily scalable physical process and are freeze-dried, enabling their room temperature storage or transport with long-term stability.
RMPs are administered systemically and can be used either therapeutically or prophylactically prior to surgical procedures with a high risk of significant blood loss. RMPs hold the potential for single agent use or for use as a complement to locally administered, conventional hemostatic agents.
RMPs do not trigger clotting themselves but normalize and accelerate the normal clotting process once it is underway, thereby preventing or arresting excessive bleeding. They can address all types of bleeding defects, whether associated with platelet function or coagulation problems, and can halt bleeding even when the exact source of the bleed is unknown. Moreover, RMPs can potentially reverse unwanted effects of otherwise irreversible coagulation therapies during a bleeding episode.
RxMP’s lead product, RMP-HPE is currently in preclinical development, with clinical trials planned for 2016. The company also has additional 2nd generation RMP candidates in earlier stages of discovery research.